Stem Cell Network
11
3
6
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 11 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
A Study Testing an Improved Dose of UM171 to Help Make Cord Blood Transplants More Effective and Safe.
Role: collaborator
UM171 Expanded Cord Blood In Patients With High-Risk Acute Leukemia/Myelodysplasia
Role: collaborator
A Phase I Double Blind Study of Metformin Acting on Endogenous Neural Progenitor Cells in Children and Young Adults With Multiple Sclerosis
Role: collaborator
The Enhanced Angiogenic Cell Therapy - Acute Myocardial Infarction Trial
Role: collaborator
Cellular Therapy for Extreme Preterm Infants at Risk of Developing Bronchopulmonary Dysplasia
Role: collaborator
Mesenchymal Stromal Cell Therapy to Prevent Bronchopulmonary Dysplasia in Extreme Preterm Infants
Role: collaborator
Umbilical Mesenchymal Stromal Cells as Cellular Immunotherapy for Septic Shock
Role: collaborator
A Phase I, Single-blind, Randomized Study of the Safety and Efficacy of Cellularized Integra® Using Autologous Burn-derived Stem Cells
Role: collaborator
Cellular Immuno-Therapy for COVID-19 Acute Respiratory Distress Syndrome
Role: collaborator
Expanded Cord Blood in Patients in Need of an Allogeneic Stem Cell Transplant
Role: collaborator
Cellular Immunotherapy for Septic Shock
Role: collaborator
All 11 trials loaded